Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$20.8MCash on Hand
9.7mo Cash Runway
Follow CMMB by emailGet an email when CMMB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CMMB, unsubscribe in one click. Privacy
📣 What CMMB Says Is Next
first half of 2028 · “Upon completion of the Merger, the combined company is expected to operate as Scipher Medicine Corporation and trade on the Nasdaq Capital Market under the ticker symbol “SCIP.” The combined company plans to initially focus on advancing nebokitug, a first-in-class clinical-stage anti-CCL24 antibody, into a Phase 2 clinical trial for the treatment of rheumatoid arthritis, with topline results expected in the first half of 2028.”
Company press release, Aug 19, 2026 · SEC filing
in 2026 · “Planned Phase 2 study overview Together with Scipher, we expect to complete pre-IND activities and submit an IND in 2026; The combined company expect to obtain IND approval and begin Phase 2 recruitment in the first half of 2027; complete enrollment during the second half of 2027; and report 12-week Phase 2 data in the first half of 2028.”
Company press release, Aug 19, 2026 · SEC filing
H1 2028 · “A topline readout of the RA Phase 2 trial results is expected in H1 2028.”
Company press release, Jul 8, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 30, 2026 ·
Deal Chemomab and Scipher Medicine agreed to a merger, with Chemomab's Israeli parent domesticating to Delaware first. Chemomab holders expected to own about 32% of the combined company. Scipher's 2026 notes convert into shares and 2025 notes are cancelled. Form DEFM14A · SEC filing
Oct 19, 2026 ·
Deal Chemomab amended its merger agreement with Scipher Medicine to cut the number of Chemomab Parent shares to be issued in the domestication merger from 10,000,000 to 5,000,000, and amended the CVR agreement to require quarterly status reports to CVR holders. Form 6-K · SEC filing
Sep 30, 2026 ·
Deal Chemomab amended its domestication merger agreement with Scipher Medicine so the combined company will have 10,000,000 shares outstanding after closing. The amendment sets a formula-based exchange ratio and addresses fractional shares, equity awards and CVRs, with the merger expected to close in Q4 2026. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2025 · Phase 2 · Results Expected · CM-101 in PSC Patients -The SPRING Study Registry primary completion date, not a results date
Aug 2022 · Phase 2 · Results Expected · CM-101 in NASH Patients - The SPLASH Study Registry primary completion date, not a results date
Apr 2020 · Phase 1 · Results Expected · The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects Registry primary completion date, not a results date
May 2019 · Phase 1 · Results Expected · Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Registry primary completion date, not a results date
Feb 2018 · Phase 1 · Results Expected · Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CMMB holds $20.8M in cash and short-term investments (as of Mar 31, 2023) and burns about $6.4M/quarter from operations,
an estimated runway of 9.7 months at that rate (BioRadar estimate, not company guidance).
Share count 575,381,320 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CMMB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CMMB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.